| Document |
Document Title |
|
WO/2005/063699A1 |
The present invention provides N-aryloxypropanolyl-N’-phenethyl-urea derivatives of formula (3), method for their preparation and use thereof as potent appetite suppressants for treatment of obesity. Formula (3): wherein R is selected ...
|
|
WO/2005/063222A1 |
An Hsp90 family protein inhibitor which contains as an active ingredient a benzene derivative represented by the following general formula (I), a prodrug thereof, or a pharmacologically acceptable salt of either.
|
|
WO/2005/063018A1 |
Present invention relates to a haloalkene compound of the formula (I)or its salt: wherein each of X1 and X2 is halogen; Y is alkyl, haloalkyl or phenyl; n is 0 to 5; L is -C(=B)Q, -C(=B)B’Q, -C(=B)N(D)Q, -N(D)Q, -N(D)C(=B)Q, -N(D)C(=B)...
|
|
WO/2005/061445A1 |
Methods and reagents for rhodium-promoted carbonylation via isocyanate using carbon-isotope labeled carbon monoxide are provided. The resultant carbon isotope labeled compounds are useful as radiopharmaceuticals, especially for use in ...
|
|
WO/2005/061443A2 |
The invention relates to benzoyl-substituted phenylalanine amides of formula (I), wherein the variables R1 to R15 have the meanings indicated in the description, the agriculturally useful salts thereof, methods and intermediate products ...
|
|
WO2005020899A3 |
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
|
|
WO/2005/058798A2 |
Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
|
|
WO2005033230A3 |
Low-cure powder coating compositions are disclosed, comprising at least one epoxy-containing resin and/or at least one siloxane-containing resin, and at least one material having the structure formula (I) wherein R1 is an organic radic...
|
|
WO/2005/056519A1 |
The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl optional...
|
|
WO/2005/056520A1 |
This invention relates to a group of novel somatostatin receptor subtype 1 (SSTR1) active compounds and pharmaceutical compositions comprising said compounds. Furthermore, the invention concerns the use of said compounds for the treatmen...
|
|
WO2002068380A8 |
The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
|
|
WO2005037798A3 |
The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for trea...
|
|
WO2005009943A3 |
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...
|
|
WO2004052845A8 |
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent acti...
|
|
WO2005028445A3 |
Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated;. R <1> is halogen, hydroxy, C 1-6 álkyl,...
|
|
WO/2005/047249A1 |
The present invention relates to compounds which are CCR-5 receptor antagonists of the general formula (I) wherein R1, R2, R3, R4, Ra, Rb, Rc, Rd, X, m and n are as defined herein. The invention further comprises pharmaceutical compositi...
|
|
WO2005015158A9 |
The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or subunits thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1...
|
|
WO/2005/044787A1 |
Compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example ...
|
|
WO/2005/044810A1 |
&agr -, β-, and &gammad -amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Fo...
|
|
WO/2005/044007A1 |
A pesticide having stabilized high pesticidal effects for crop plants infected with plant diseases, is presented. The pesticide contains a biphenyl derivative represented by the formula (I) or its salt, as an active ingredient: wherein X...
|
|
WO/2005/044786A1 |
This invention relates to bicyclic amide, carbamate or urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The bicyclic amide, carbamate or urea derivative of the present invention ha...
|
|
WO/2005/044788A1 |
A process for producing a compound (C) represented by the formula (C) (wherein R1 means hydrogen, C1-6 alkyl, or C3-8 cycloalkyl; and R2 means hydrogen or methoxy), characterized by reacting a compound (A-1) represented by the formula (A...
|
|
WO/2005/041684A2 |
The present invention relates to the discovery that certain non-naturally occurring, non-peptide arride compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavorin...
|
|
WO2005000803A8 |
A process for producing an asymmetric compound (IV), characterized by causing a compound (II) to add a nucleophilic reagent (III) through conjugate addition in the presence of an asymmetric urea compound (I). Also provided is a nonmetall...
|
|
WO/2005/040101A1 |
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These c...
|
|
WO/2005/040100A1 |
This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have ...
|
|
WO/2005/040355A2 |
The invention provides compounds and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compounds for modulating protein kinase enzymatic activity ...
|
|
WO/2005/037798A2 |
The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for trea...
|
|
WO2005007091A3 |
One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neu...
|
|
WO2004062601A3 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...
|
|
WO/2005/035471A1 |
An ether derivative represented by the formula (I) or a pharmaceutically acceptable salt, hydrate, or solvate thereof: (I) (wherein the symbols are the same as defined in the description) and an ether derivative represented by the formul...
|
|
WO/2005/033230A2 |
Low-cure powder coating compositions are disclosed, comprising at least one epoxy-containing resin and/or at least one siloxane-containing resin, and at least one material having the structure formula (I) wherein R1 is an organic radic...
|
|
WO2004103281A3 |
One aspect of the invention relates to antagonists of mammalian vanilloid receptors. Another aspect of the invention relates to a method of modulating the activity of a vanilloid receptor in a mammal, comprising administering a compound ...
|
|
WO/2005/028445A2 |
Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated;. R 1 is halogen, hydroxy, C 1-6 álkyl, h...
|
|
WO2005007732A3 |
Provided herein are polyurea polymers made from an organic isocyanate and a polyamine component, wherein the polyamine component comprises a polyether polyamine in which the nitrogen atoms are secondary. The polyurea polymers of the inve...
|
|
WO2004064730A3 |
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
|
|
WO2004046162A8 |
ABSTRACT Potent non-steroidal farnesoid X receptor (FXR) agonists are N-aryl-N-arylmethyl amido and ureido compounds having the chemical structure represented by the following formula (I): INSERT FORMULA wherein E1 is (C1-C8)alkyl, cyclo...
|
|
WO/2005/020899A2 |
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
|
|
WO/2005/021499A1 |
The present application describes modulators of MCP-1 of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
|
|
WO/2005/019174A1 |
The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositio...
|
|
WO2005000803A3 |
A process for producing an asymmetric compound (IV), characterized by causing a compound (II) to add a nucleophilic reagent (III) through conjugate addition in the presence of an asymmetric urea compound (I). Also provided is a nonmetall...
|
|
WO/2005/015158A2 |
The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or subunits thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1...
|
|
WO/2005/012231A1 |
An aminocarbonyl naphthol derivative represented by the formula (1) below and a method for producing the same. (1) (In the formula (1), Y1 and Y2 represent a group selected from the group consisting of aminocarbonyl groups, carboxyl grou...
|
|
WO2004077511A3 |
The present invention provides novel (meth)acrylic and (meth)acrylamide monomers and polymers produced from those monomers. The monomers of the invention each include only a single vinyl functionality and at least one non-vinyl functiona...
|
|
WO/2005/009940A1 |
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
|
|
WO/2005/009944A1 |
The invention pertains to prodrugs of 9-aminomethyl substituted tetracycline compounds, methods of using the compounds, and pharmaceutical compositions containing them.
|
|
WO/2005/009943A2 |
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...
|
|
WO/2005/007732A2 |
Provided herein are polyurea polymers made from an organic isocyanate and a polyamine component, wherein the polyamine component comprises a polyether polyamine in which the nitrogen atoms are secondary. The polyurea polymers of the inve...
|
|
WO/2005/007621A2 |
This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides f...
|
|
WO/2005/007091A2 |
One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neu...
|
